RT @ejdein1: #EULAR2021 POS0226 Bimekizumab (anti-IL17A and IL-17F) 160 mg Q4w for AS, 3yr phase 2b, open-label extensio
Tweet Content
#EULAR2021 POS0226 Bimekizumab (anti-IL17A and IL-17F) 160 mg Q4w for AS, 3yr phase 2b, open-label extension wk 48-156). Efficacy sustained ASAS40 63%. AEs: pharyngitis, URI, bronchitis, ⬆️ ALT, oral candida (mild/mod). @RheumNow.
Show on Archive Page
On
Display in Search Results
On
PDQ
Off